HIV-1 tat protein suppresses cholangiocyte toll- like receptor 4 expression and defense against cryptosporidium parvum

Journal of Infectious Diseases

Volumn 199, Issue 8, 2009, Pages 1195-1204

  O'Hara, Steven P ^a   Small, Aaron J ^c   Gajdos, Gabriella B ^a   Badley, Andrew D ^b   Chen, Xian Ming ^d   LaRusso, Nicholas F ^a,e  

^a Miles and Shirley Fiterman Center for Digestive Diseases   (United States)

^b Mayo Clinic   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DISEASE PREDISPOSITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN METABOLISM; RECEPTOR BINDING; TRANSCRIPTION INITIATION; TRANSLATION INITIATION;

ANIMALS; BILE DUCTS; CELL LINE, TRANSFORMED; CRYPTOSPORIDIUM PARVUM; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; RECOMBINANT PROTEINS; RNA, MESSENGER; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TOLL-LIKE RECEPTOR 4;

EID: 65649149370     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597387     Document Type: Article

References (45)

1. Chen XM, Keithly JS, Paya CV, LaRusso NF. Current concepts: cryptosporidiosis. New Engl J Med 2002; 346:1723-31.
2. Clark DP. New insights into human cryptosporidiosis. Clin Microbiol Rev 1999; 12:554-63.
3. Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis 1997; 3:51-7.
4. Hunter PR, Nichols G. Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev 2002; 15:145-54.
5. Leav BA, Mackay M, Ward HD. Cryptosporidium species: new insights and old challenges. Clin Infect Dis 2003; 36:903-8.
6. Dimicoli S, Bensoussan D, Latger-Cannard V, et al.Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. Bone Marrow Transplant 2003; 32:733-7.
7. Hayward AR, Levy J, Facchetti F, et al.Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158:977-83.
8. Manabe YC, Clark DP, Moore RD, et al.Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis 1998; 27:536-42.
9. Wilcox CM, Monkemuller KE. Hepatobiliary diseases in patients with AIDS: focus on AIDS cholangiopathy and gallbladder disease. Dig Dis 1998; 16:205-13.
10. McDonald V. Host cell-mediated responses to infection with Cryptosporidium. Parasite Immunol 2000; 22:597-604.
11. Chen XM, O'Hara SP, Nelson JB, et al.Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappa B. J Immunol 2005; 175:7447-56.
12. Chen X-M, Splinter PL, O'Hara SP, LaRusso NF. A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 2007; 282:28929-38.
13. Cao YZ, Dieterich D, Thomas PA, Huang YX, Mirabile M, Ho DD. Identification and quantitation of HIV-1 in the liver of patients with AIDS. AIDS 1992; 6:65-70.
14. Housset C, Lamas E, Courgnaud V, et al.Presence of HIV-1 in human parenchymal and nonparenchymal liver-cells in-vivo. J Hepatol 1993; 19:252-8.
15. Jeang KT, Xiao H, Rich EK. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 1999; 274:28837-40.
16. Siliciano RF. The role of CD4 in HIV envelope-mediated pathogenesis. Curr Top Microbiol Immunol 1996; 205:159-79.
17. Townsley-Fuchs J, Neshat MS, Margolin DH, Braun J, Goodglick L. HIV-1 gp120: a novel viral B cell superantigen. Int Rev Immunol 1997; 14:325-38.
18. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285:1569-72.
19. Mayer HB, Wanke CA, Du B, Hammer SM, Terwilliger EF. HIV-1 Tat modulates invasion by a bacterial enteric pathogen into a human intestinal-cell line. AIDS 1995; 9:1237-42.
20. Canani RB, Cirillo P, Mallardo G, et al.Effects of HIV-1 Tat protein on ion secretion and on cell proliferation in human intestinal epithelial cells. Gastroenterology 2003; 124:368-76.
21. Bennasser Y, Le SY, Benkirane M, Jeang KT. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005; 22: 607-19.
22. Grubman SA, Perrone RD, Lee DW, et al.Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial-cell lines. Am J Physiol 1994; 266:G1060-70.
23. Xiao H, Neuveut C, Tiffany HL, et al.Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000; 97:11466-71.
24. Poggi A, Zocchi MR. HIV-1 Tat triggers TGF-beta production and NK cell apoptosis that is prevented by pertussis toxin B. Clin Dev Immunol 2006; 13:369-72.
25. Chen XM, Gores GJ, Paya CV, LaRusso NF. Cryptosporidium parvum induces apoptosis in biliary epithelia by a Fas/Fas ligand-dependent mechanism. Am J Physiol 1999; 277:G599-608.
26. O'Hara SP, Yu JR, Lin JJC. A novel Cryptosporidium parvum antigen, CP2, preferentially associates with membranous structures. Parasitol Res 2004; 92:317-27.
27. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol 2000; 164:966-72.
28. Zuker M, Mathews DH, Turner DH. In: Barciszewski J, Clark BFC, eds. RNA biochemistry and biotechnology. NATO ASI Series. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1999:2-12.
29. Mathews DH, Sabina J, Zuker M, Turner DH. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999; 288:911-40.
30. Kingsman SM, Kingsman AJ. The regulation of human immunodeficiency virus type-1 gene expression. Eur J Biochem 1996; 240:491-507.
31. Vene R, Benelli R, Noonan DM, Albini A. HIV-Tat dependent chemotaxis and invasion, key aspects of Tat mediated pathogenesis. Clin Exp Metastasis 2000; 18:533-8.
32. Ensoli B, Buonaguro L, Barillari G, et al.Release, uptake, and effects of extracellular human-immunodeficiency-virus type-1 Tat protein on cell-growth and viral transactivation. J Virol 1993; 67:277-87.
33. Richter S, Ping YH, Rana TM. TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci USA 2002; 99:7928-33.
34. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9- associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92:451-62.
35. Garber ME, Wei P, Jones KA. HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Cold Spring Harb Symp Quant Biol 1998; 63:371-80.
36. Tai NW, Schmitz JC, Chen TM, Chu E. Characterization of a cis-acting regulatory element in the protein-coding region of human dihydrofolate reductase mRNA. Biochem J 2004; 378:999-1006.
37. Butcher NJ, Broadhurst GM, Minchin RF. Polyamine-dependent regulation of spermidine-spermine N-1-acetyltransferase mRNA translation. J Biol Chem 2007; 282:28530-9.
38. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76.
39. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
40. Modlin RL, Cheng GH. From plankton to pathogen recognition. Nat Med 2004; 10:1173-4.
41. Campos MA, Closel M, Valente EP, et al.Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol 2004; 172:1711-8.
42. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95.
43. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1- associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256-61.
44. Ko WF, Cello JP, Rogers SJ, Lecours A. Prognostic factors for the survival of patients with AIDS cholangiopathy. Am J Gastroenterol 2003; 98:2176-81.
45. O'Hara SP, Small AJ, Nelson JB, et al.The human immunodeficiency virus type 1 Tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism. Infect Immun 2007; 75:684-96.